Etoposide

SEP 11, 2026 · PHASE 2 TRIAL

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 2 trial registration with no results reported; it describes a planned study of an investigational drug in combination therapy for extensive-stage SCLC, addressing dose optimization and safety.

SEP 10, 2026 · PHASE 3 TRIAL

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

ClinicalTrials.gov

This is a completed phase 3 trial registration with no results posted; the primary outcome measure and follow-up duration are listed but no efficacy or safety data are reported in this registry record.

SEP 9, 2026 · PHASE 3 TRIAL

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record for an active Phase 3 study with no results posted; the record describes planned design and enrollment only.

SEP 8, 2026 · PHASE 3 TRIAL

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

ClinicalTrials.gov

This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.

AUG 17, 2026 · PHASE 3 TRIAL

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

ClinicalTrials.gov

This is a Phase 3 RCT registration with no results posted; the study is actively recruiting and outcomes have not yet been reported.

AUG 14, 2026 · PHASE 3 TRIAL

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

ClinicalTrials.gov

This is a Phase 3 trial registration with no results reported; the study is actively recruiting and outcome data are not yet available.

AUG 11, 2026 · PHASE 3 TRIAL

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 3 trial registration with no reported results; the study is active but not yet recruiting and outcome data are not posted in this registry record.